New Chronic Myeloid Leukemia Findings from Huazhong University of Science and Technology Described (Clinical Pharmacokinetics and Drug-drug Interactions of Tyrosine-kinase Inhibitors In Chronic Myeloid Leukemia: a Clinical Perspective).

Researchers from Huazhong University of Science and Technology in Wuhan, China have conducted a study on the pharmacokinetics and drug-drug interactions of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML). TKIs have been widely used in CML treatment, but their pharmacokinetics can vary greatly between patients, leading to potential drug-drug interactions that can affect therapy outcomes. The study provides a comprehensive overview of the absorption, distribution, metabolism, and excretion profiles of TKIs, as well as their use in special populations and known or suspected interactions with other drugs. The research aims to guide healthcare professionals in managing drug-drug interactions during TKI treatment. [Extracted from the article]

Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)